- GeneDx to Participate in Upcoming Investor Conferences
- GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
- GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
- GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
- GeneDx to Participate in 44th Annual Cowen Health Care Conference
- GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
- GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
- GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GeneDx Announces Preliminary 2023 Financial Results
More ▼
Key statistics
On Wednesday, GeneDx Holdings Corp (WGS:NSQ) closed at 19.99, -18.07% below its 52-week high of 24.40, set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.51 |
---|---|
High | 21.44 |
Low | 19.88 |
Bid | 19.64 |
Offer | 24.00 |
Previous close | 20.75 |
Average volume | 583.19k |
---|---|
Shares outstanding | 26.15m |
Free float | 17.96m |
P/E (TTM) | -- |
Market cap | 542.63m USD |
EPS (TTM) | -5.25 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼